Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says
Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.
How this was made
The 30-second read
Why it matters
The buy rating and higher target could attract momentum traders and reinforce long positions.
Market read
Analyst upgrade adds fresh bullish catalyst for a high‑growth pharma stock, likely influencing sector sentiment.
What to watch
Potential pricing pressure from insurers and the need for sustained reimbursement approvals.
Background
Eli Lilly's stock has risen 52% over the past year on GLP‑1 sales; the upgrade reflects continued optimism.
Ticker impact
Berenberg upgraded Eli Lilly to buy and raised the price target to $1,400, marking a fresh analyst recommendation.
Potential 2‑3% price gain in the next trading session.
Upgrade comes with a higher target and aligns with strong GLP‑1 demand, supporting bullish bias.
Market effects
Weight‑loss and diabetes drug sector may see broader rally as GLP‑1 pipeline gains momentum.
U.S. pharma stocks could benefit from heightened investor interest.
Global biotech investors may re‑price exposure to obesity therapeutics.
Counterpoint
The upgrade may be premature if upcoming competition intensifies or regulatory hurdles delay new GLP‑1 launches.
Key entities
- companyEli Lilly (LLY)
Pharmaceutical company producing Mounjaro and Zepbound.
- analyst_firmBerenberg
Equity research house that issued the upgrade.
